Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 28007287.
- Also identified by DOI 10.1016/j.athoracsur.2016.06.068.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Management of heparin-induced thrombocytopenia (HIT) entails cessation of heparin and initiation of a nonheparin parenteral anticoagulant such as danaparoid. Danaparoid cross-reactivity with HIT antibodies is an uncommon complication of treatment of HIT. We report the case of confirmed HIT and in vivo cross-reactivity with danaparoid, complicating severe sepsis due to an infectious endocarditis treated by cardiac surgery.
Medical subject headings
- Cardiac Surgical Procedures
- Chondroitin Sulfates
- Dermatan Sulfate
- Heart Valve Diseases
- Heparin
- Heparan Sulfate
- Thrombocytopenia